# AlphaMol

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alphamol

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.alphamol.com
- Latest round: Series B (Nov 16, 2025)
- Investors on record: 5

## About

Established in 2020 and based in Shenzhen, China, ALPHAMOL SCIENCE LTD, trading as AlphaMol, is a biopharmaceutical company incubated by the Shenzhen Institute of Advanced Technology under the Chinese Academy of Sciences, focusing on AI-assisted new drug research and development. The company has factories in Basel, Switzerland, as well as in Shanghai and Shenzhen, China. In addition, it has four major research departments including: Computational Drug Discovery, Medicinal Chemistry, Cell Biology and Biochemistry, and Pharmacology. The founding partners of this company, academics Horst Vogel and Dr. Shuguang Yuan, have both been named to the top 2% of the world's leading scientists. The science and technology team participated in the global GPCR-DOCK computer predictive modeling competition and beat Google AlphaFold2 in the prediction of the spatial structure of the relevant target, and won second, third, and fifth place in the world. In November 2025, AlphaMol closed Series B funding from new investors Ningbo Meishan Bonded Port Ruifeng Investment and CICC Capital. 
The company's self-developed products include a biochip to test G protein-coupled receptor proteins (GPCR), a biochip to test cellular electrophysiology, and a biochip to track single-molecule cells. It has also developed a GPCR (G-protein-coupled receptors) drug discovery platform that enables efficient screening, design and optimization of drug molecules and rapid access to clinical candidate molecules. In addition, its product pipeline includes bifunctional anticancer drugs, infection drugs, low-side effect painkillers, cancer drugs and metabolic drugs. 
The company generates revenue by developing and providing AI-assisted drug and other related products.

## Funding rounds

- Series B, Nov 16, 2025 — China International Capital Corporation, Ningbo Meishan Bonded Port Ruifeng Investment
- Series A, Aug 24, 2023 — New Value Capital, Shanghai Healthcare Capital, Huaqian Capital

## Investors

- New Value Capital — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A
- Huaqian Capital (https://capitalatlas.ai/funds/huaqian-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Ningbo Meishan Bonded Port Ruifeng Investment — Series B